Latest News

Sensyne Health inks collaboration deal with Bristol Myers Squibb – it’s fourth partnership with a ma


Sensyne Health PLC (LON:SENS) shares rose on Friday after news the firm has agreed a research collaboration with Bristol Myers Squibb that will see it deploy its artificial intelligence and machine learning technology to help better understand certain rare blood diseases.

Work will focus on Myeloproliferative Neoplasms to assess the progression of these blood cancers that are characterised by the over-production of white or red cells, or platelets.

The pair will also categorise patients into groups and sub-groups according to type and severity of disease (a process called stratification). No financial terms were disclosed.

This is Sensyne’s fourth partnership with a major pharma company following deals with Bayer, Roche and Alexion.

“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the ethical commercialisation of such data,” Sensenye chief executive Lord Drayson said in a statement.

“As we continue to see wider adoption of clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”

Headed by former science minister and serial entrepreneur, Lord Drayson, Sensyne specialises in the ethical application of clinical artificial intelligence and machine learning.

Practically, this means it develops software that connects clinicians with patients, while also working with NHS trusts to garner insights from data using technology developed in partnership with Oxford University.

The NHS holds cradle-to-grave health data that is now largely digitised and focused on medical outcomes.

By applying AI, Sensyne is aiming to unearth crucial new information that could improve clinical trial success rates, reduce approval times, or even help researchers find new drug targets.

In morning trading, Sensyne shares were 6.5% higher at 98.50p.

  — Adds share price, analyst comment —

Kavango surges after latest update on the Kalahari Suture Zone

Previous article

TUI, easyJet rejoice after UK drops quarantine for Canary Islands, Mykonos

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Latest News